Kenvue Inc. (NYSE:KVUE) Shares Purchased by Brown Advisory Inc.

Brown Advisory Inc. boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 0.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,730,822 shares of the company’s stock after acquiring an additional 1,792 shares during the period. Brown Advisory Inc. owned about 0.09% of Kenvue worth $36,953,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Norges Bank acquired a new stake in Kenvue in the fourth quarter worth $521,348,000. Franklin Resources Inc. increased its holdings in shares of Kenvue by 61.5% in the 4th quarter. Franklin Resources Inc. now owns 42,719,377 shares of the company’s stock worth $912,059,000 after acquiring an additional 16,269,721 shares during the period. Massachusetts Financial Services Co. MA lifted its position in Kenvue by 12.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 97,661,344 shares of the company’s stock valued at $2,085,070,000 after purchasing an additional 10,682,003 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Kenvue by 3.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 245,885,918 shares of the company’s stock valued at $5,249,665,000 after purchasing an additional 8,211,748 shares during the period. Finally, Boston Partners grew its position in Kenvue by 36.9% in the 4th quarter. Boston Partners now owns 23,595,963 shares of the company’s stock worth $503,145,000 after purchasing an additional 6,366,097 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Stock Performance

Kenvue stock opened at $23.63 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market cap of $45.34 billion, a P/E ratio of 44.58, a price-to-earnings-growth ratio of 2.62 and a beta of 1.02. Kenvue Inc. has a fifty-two week low of $17.67 and a fifty-two week high of $24.46. The firm’s 50 day simple moving average is $23.10 and its 200-day simple moving average is $22.53.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, equities research analysts predict that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 28th. Investors of record on Wednesday, May 14th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.47%. The ex-dividend date of this dividend is Wednesday, May 14th. Kenvue’s dividend payout ratio is currently 154.72%.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Redburn Atlantic initiated coverage on Kenvue in a research note on Thursday, April 10th. They set a “neutral” rating and a $23.50 target price on the stock. Barclays decreased their target price on shares of Kenvue from $23.00 to $22.00 and set an “equal weight” rating for the company in a research report on Monday, April 14th. Citigroup upped their price target on shares of Kenvue from $21.00 to $22.00 and gave the stock a “neutral” rating in a research note on Monday, April 14th. UBS Group cut their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Finally, Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Eight investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, Kenvue presently has an average rating of “Hold” and an average price target of $24.42.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.